MyLungCancerTeam

While CEA testing can be part of monitoring lung cancer, current medical guidelines emphasize biomarker testing as a more critical tool for NSCLC treatment decisions. Biomarker testing helps identify specific genetic mutations and proteins like PD-L1 that can determine which targeted therapies or immunotherapies might work Show Full Answer

While CEA testing can be part of monitoring lung cancer, current medical guidelines emphasize biomarker testing as a more critical tool for NSCLC treatment decisions. Biomarker testing helps identify specific genetic mutations and proteins like PD-L1 that can determine which targeted therapies or immunotherapies might work best for your particular case.

Only about 29% of lung cancer patients currently receive or are scheduled for biomarker testing, though it's considered essential for optimal treatment outcomes. If you haven't had biomarker testing yet, it's worth discussing with your oncologist. The results can:
- Help match you with the most effective targeted treatments
- Determine if you're a good candidate for specific clinical trials
- Guide your overall treatment plan

Note that getting biomarker test results may take several weeks, as adequate tissue samples are needed and processing times vary.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

77% of MyLungCancerTeam Members Are Satisfied With Their Doctors, Survey Finds

Community Clinics Lag in Biomarker Testing for Lung Cancer Treatment, Survey Finds